Latest Regulatory Approval News

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

St George Mining Limited progresses its strategic acquisition of the Araxá Niobium-REE Project while reporting promising exploration results across multiple Australian projects, underpinning its critical metals ambitions.

Bounty Oil and Gas NL reports steady cash reserves and rising oil production in Queensland, while facing regulatory setbacks offshore. The company’s strategic developments and entitlement offer position it for growth in 2025.

Poseidon Nickel Limited and Horizon Minerals Limited have secured decisive shareholder approval for their merger via schemes of arrangement, marking a pivotal step toward creating a new mid-cap mining entity in Western Australia.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Classic Minerals Limited has agreed to sell its Kat Gap gold tenements to Bain Global Resources for A$7 million, aiming to reduce debt and refocus on other exploration projects. The deal awaits shareholder approval and regulatory clearances.

LCL Resources has executed a binding agreement to divest its Colombian assets for A$10 million, while confirming a significant copper-gold porphyry discovery at its Dada project in Papua New Guinea.

Alligator Energy reports significant progress across its uranium portfolio, including regulatory milestones at Samphire and promising drilling results at Big Lake and Nabarlek North, supported by a solid cash position of $20.2 million.

Mindax Limited progresses its Mid-West Shared Infrastructure Project and seeks development partners for the Mt Forrest Iron Project, while securing a significant R&D tax incentive refund.

Triton Minerals has secured A$17 million from the sale of a 70% stake in its Mozambique graphite assets, while progressing environmental approvals and unveiling promising high-grade gold and copper results at its new Aucu project.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.